Vortioxetine for the treatment of major depressive disorder. Issue 6 (November 2014)

• Record Type: Journal Article
• Authors: Tritschler, Laurent; Felice, Daniela; Colle, Romain; Guilloux, Jean-Philippe; Corruble, Emmanuelle; Gardier, Alain Michel; David, Denis Joseph
• Is Part Of: Expert review of clinical pharmacology. Volume 7:Issue 6(2014)
• Page Start: 731
• Page End: 745
• Publication Date: 2014-11
• Subjects: Clinical pharmacology -- Periodicals; 615.105
• DOI: 10.1586/17512433.2014.950655
• Languages: English
• ISSNs: 1751-2433

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <p>Vortioxetine (Brintellix^®, 1-[2-(2, 4-dimethylphenyl-sulfanyl)-phenyl]-piperazine) is a multimodal antidepressant targeting the 5-HT_1A, 5-HT_1B, 5-HT_1D, 5-HT₃, 5-HT₇ receptors and the serotonin (5-HT) transporter (5-HTT). Vortioxetine administration induces antidepressant- and anxiolytic-like effects, and can enhance cognitive performance in rodents. Several clinical trials have reported the efficiency and a satisfactory tolerability of vortioxetine treatment in depressed patients. Remarkably, vortioxetine has a specific positive impact on cognitive symptoms in depressed patients. Overall, vortioxetine is an efficacious antidepressant drug for the treatment of patients with a major depressive episode and has a unique mechanism of action offering a new therapeutic option.</p> </abstract>